2005-12-09
Barrett’s Esophagus: a Molecular Characterization
Publication
Publication
Barrett-oesofagus: een moleculaire karakteristiek
Barrett’s esophagus is a premalignant condition that is most likely caused by gastroesophageal reflux. In the western world, about 30% of adults have reflux complaints, such as heartburn, and about 10% of reflux patients will develop Barrett’s esophagus [1]. Barrett’s esophagus is characterized by chronic inflammation, and like other chronic inflammatory lesions, it is associated with cancer development. Patients with Barrett’s esophagus have a 30 times increased risk for the development of esophageal adenocarcinoma compared to the general population. Barrett’s esophagus can progress to esophageal adenocarcinoma through the intermediate stages low-grade dysplasia and high-grade dysplasia [3]. Esophageal adenocarcinoma has a poor prognosis, the overall survival is only 15-20%.
| Additional Metadata | |
|---|---|
| , | |
| AstraZeneca, Department of Gastroenterology and Hepatology, Erasmus MC, Jurriaanse Stichting, Kuipers, Prof. Dr. E.J. (promotor), NVGE, section experimental gastroenterology, Pfizer, Roche Diagnostics | |
| E.J. Kuipers (Ernst) | |
| Erasmus University Rotterdam | |
| hdl.handle.net/1765/10564 | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Bax, D. (2005, December 9). Barrett’s Esophagus: a Molecular Characterization. Retrieved from http://hdl.handle.net/1765/10564 |
|
